(4S)-6-bromo-2,2-dimethyl-2'-propyliminospiro[3H-chromene-4,5'-imidazolidine]-4'-one
C16H20BrN3O2 — CID 135418466
Data last refreshed: (MolForge compound catalog, from PubChem)
About (4S)-6-bromo-2,2-dimethyl-2'-propyliminospiro[3H-chromene-4,5'-imidazolidine]-4'-one
(4S)-6-bromo-2,2-dimethyl-2'-propyliminospiro[3H-chromene-4,5'-imidazolidine]-4'-one (PubChem CID 135418466) has the molecular formula C16H20BrN3O2 and a molecular weight of 366.26 g/mol. Its IUPAC name is (4S)-6-bromo-2,2-dimethyl-2'-propyliminospiro[3H-chromene-4,5'-imidazolidine]-4'-one.
Molecular Properties
| Compound Name | (4S)-6-bromo-2,2-dimethyl-2'-propyliminospiro[3H-chromene-4,5'-imidazolidine]-4'-one |
|---|---|
| PubChem CID | 135418466 |
| Molecular Formula | C16H20BrN3O2 |
| Molecular Weight | 366.26 g/mol |
| Exact Mass | 365.07 |
| IUPAC Name | (4S)-6-bromo-2,2-dimethyl-2'-propyliminospiro[3H-chromene-4,5'-imidazolidine]-4'-one |
| SMILES | CCC/N=C1\NC(=O)[C@@]2(CC(C)(C)Oc3ccc(Br)cc32)N1 |
| InChI | InChI=1S/C16H20BrN3O2/c1-4-7-18-14-19-13(21)16(20-14)9-15(2,3)22-12-6-5-10(17)8-11(12)16/h5-6,8H,4,7,9H2,1-3H3,(H2,18,19,20,21)/t16-/m0/s1 |
| InChIKey | SKABRRBNTBHDTE-INIZCTEOSA-N |
| XLogP | 2.69 |
| TPSA | 62.72 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 3 |
| Rotatable Bonds | 2 |
| Heavy Atoms | 22 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 366.26 |
| LogP ≤ 5 | 2.69 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 3 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'imine_1', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 135418466 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.